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Running title: Validity of SF-MPQ2 Neuropathic Subscale

ABSTRACT
Objectives: The purpose of this study was to conduct classical psychometric evaluation and
Rasch analysis on the Neuropathic Qualities subscale from the Short Form McGill Pain
Questionnaire-2 utilizing scores from persons with complex regional pain syndrome to consider
reliability and person separation, validity (including unidimensionality), and responsiveness in
this population. Methods: Secondary analysis of longitudinal data from persons with acute
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complex regional pain syndrome was utilized for analysis of the psychometric properties and fit
to the Rasch model of the Neuropathic Qualities subscale. We followed an iterative process of
Rasch analysis to evaluate and address data fitting challenges. Results: Repeated measures from
n=59 persons meeting the Budapest criteria were used for analysis. Both item-total correlations
and unidimensionality analyses supported theoretical construct validity; all convergent construct
validity hypotheses were also supported. Responsiveness was demonstrated comparing baseline
and one-year data at d= 0.92, with a standardized response mean of 0.97. Data were able to fit
the Rasch model but all Neuropathic Qualities items had disordered thresholds requiring
rescoring. Additionally, local dependency and differential item function were addressed by
‘bundling’, suggesting no further item reduction would be possible. Conclusions: This study
provided preliminary support for the validity and responsiveness of the Neuropathic Qualities
subscale in persons with complex regional pain syndrome. Rasch analysis further endorses use of
the Neuropathic Qualities subscale as a ‘stand-alone’ measure for neuropathic features, but with
substantial background data transformations. Replication with larger samples is recommended to
increase confidence in these findings.
Keywords: complex regional pain syndrome, neuropathic pain qualities, Rasch analysis,
outcome measurement

3

INTRODUCTION
Complex regional pain syndrome (CRPS) is a unique pain presentation that may develop after
trauma or surgery, or spontaneously.(1) While some persons may see resolution of their
symptoms in the first year,(2) others experience persistent pain and disability.(3,4) The Special
Interest Group for CRPS of the International Association for the Study of Pain convened a
working group to develop recommendations for outcome measurement for clinical studies in
CRPS (COMPACT: Core Outcome Measurement set for complex regional PAin syndrome
Clinical sTudies). The mandate of this group was to select a recommended core set of outcome
measures to use in all clinical studies involving CRPS patients with the goal of supporting
international collaborations and future meta-analyses to advance the field of CRPS research.(5)
One of the consensus recommendations from COMPACT was to prefer the use of assessments
that had been tested using item-response theory,(5) which considers the measurement properties
invariant across populations, thus facilitating comparisons(6) of pain and disability between
persons with CRPS and other diagnostic groups (for example, painful diabetic neuropathy).
After consensus was reached, which drew substantially from the PROMIS measures(7,8) to
address many of the key constructs, the COMPACT team deliberated on what assessments of
pain qualities were concordant with this theoretical lens, or had existing data available that
would permit timely Rasch analysis to consider interval-level scoring properties.
Rasch analysis
Rasch analysis is an item-response framework based on probabilistic modelling: simply stated, it
considers the odds that any two persons with similar amounts of the trait of interest (for example,
neuropathic pain symptoms) would score the same on any given scale item. Another
conceptualization is Rasch modelling calculates the observed vs predicted values for each item
on a scale across all persons in the sample, and the observed vs predicted values for each person
across items. These predicted values are generated from other scores or known characteristics,
also called person factors, and from the item scales themselves. Thus items and person are ‘fit’
to the Rasch model, using person ability and item difficulty. Accordingly, if someone reports
they are able to walk a mile without pain, it would also be predicted they would positively
answer an item about if they can easily walk a block without pain. The item about walking a
mile is more ‘difficult’ than the item about walking a block, and the person who is able to walk a
mile has more ability than someone who is only able to walk a block. Conversely, if someone
reports severe pain, we would also predict they would not positively answer an item about
walking a mile without pain. These properties or ‘locations’ of item difficulty and person
ability/disability can be visually mapped to illustrate their relationship for the particular
assessment being examined.

Developed by Danish mathematician George Rasch,(6,9) the Rasch model: 1) uses a statistical
strategy to convert the ordinal scale measurements of individual test items into interval level
scaling,(9) 2) identifies systematic bias (termed differential item functioning)across different
person-level characteristics such as gender,(10) 3) relies on large sample sizes to validate the
item characteristics (11), and 4) assumes the item measurement characteristics are not dependent
on the study population (person characteristics) if the model can be applied, and is adequately
powered.(12,13) A key theoretical element is the score of any item moves predictably from less
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difficult to more difficult (for example from 0-10, where 0 means no pain, and 10 means worst
possible pain). The point between any two scores (like 0,1 or 1,2) where the probability is 50/50
a person with a set amount ability would choose 0 vs 1 is called a threshold.(9) The orderly or
predictable progression of thresholds is a prerequisite for achieving model fit.
Rasch modelling also generates estimates of item reliability, where the focus is on how well
items are differentiated on the variable of interest (analogous to Cronbach’s alpha);(9,14) person
separation (a similar concept to reliability, where the standard error is used to describe the spread
or separation of person abilities);(9) and unidimensionality (which could be considered
analogous to content validation, or factorial validity).(15) A scale that fits the Rasch model is
assumed to reliably allow meaningful comparisons between individuals with different abilities or
attributes (like education, gender, or even diagnosis) but the same amount of whatever trait the
scale is intended to measure (for example, pain interference with walking from our previous
example).

The Short Form of the McGill Pain Questionnaire-2
One tool considered by COMPACT, for inclusion in the core assessment set for the assessment
of pain qualities, was the Neuropathic Qualities subscale (NeQ) of the second version of the
short form McGill Pain Questionnaire (SF-MPQ2).(16) The SF-MPQ2 subscale for neuropathic
qualities was considered appropriate to address the important domain of pain qualities.(5) While
many other measures of neuropathic pain are available, our concerns were 1) many were
developed with the intent to discriminate between nociceptive and neuropathic pain features,
rather than to measure the severity or impact of neuropathic pain,(17–20) or 2) lacked requisite
evidence for test-retest reliability and responsiveness.(21),(22) Further, the brevity of including a
brief scale or subscale was desirable, to minimize participant burden related to a core set of
measures. To date, psychometric studies of the measurement properties of the total SF-MPQ2
have not included substantial proportions of participants with CRPS: estimates for reliability,
validity and responsiveness arise from populations with painful diabetic neuropathy(16), cancer
pain,(23) acute low back pain,(24) or a mixture of pain diagnoses.(16,25) While the scaling
structure of the SF-MPQ2 has been validated,(16) supporting the legitimacy of each subscale as
a unique construct, we were unaware of any published studies looking at the NeQ subscale (see
Table 1 for an overview of the SF-MPQ2 items and subscales) as a distinct entity for outcome
measurement. If data generated from the NeQ subscale of the SF-MPQ2 demonstrated fit to the
Rasch model, this would support its validity as a stand-alone outcome measure for neuropathic
pain. When we set out to examine the SF-MPQ2, no Rasch analyses of the measurement
characteristics had been published. However, a recent publication reported Rasch analysis of the
SF-MPQ2 in participants with knee osteoarthritis(26) and suggested the NeQ subscale could also
fit the model. Therefore, an opportunity exists to consider the measurement properties of the
NeQ subscale of the SF-MPQ2 using Rasch modeling in a different population, and to compare
these findings to estimates of measurement properties using traditional psychometric methods
from classical test theory (CTT). This would ultimately assist pain clinicians in the selection of
evaluation tools to inform treatment planning for persons with CRPS. The purpose of this study
therefore, was to conduct both classical psychometric, and Rasch analysis on the NeQ subscale
from the SF-MPQ2 utilizing scores from participants with CRPS to consider its reliability and
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person separation, and estimate validity (including unidimensionality), and responsiveness in this
population.

Table 1. Overview of the items of the Short Form McGill Pain Questionnaire (version 2).
Continuous pain
Intermittent pain
Neuropathic pain
Affective
descriptors
Throbbing pain
Shooting pain
Hot-burning pain
Tiring-exhausting
pain
Cramping pain
Stabbing pain
Cold-freezing pain
Gnawing pain
Sharp pain
Pain caused by light
Sickening
touch
Aching pain
Splitting pain
Itching
Fearful
Heavy pain
Electric shock pain
Tingling or ‘pins and Punishing-cruel
needles’
Tender
Piercing pain
Numbness
Items are scored 0-10, with 0= no pain to 10=worst possible pain.

METHODS
Sample and Data Collection
This study represents a secondary analysis of data collected from participants with acute CRPS
(n=59) referred by community and hospital-based clinics in Auckland, New Zealand between
February 2012 and March 2014.(2,27) The aims of the study were 1) to track symptoms and
signs of in persons with CRPS in the first year of the diagnosis (2), 2) to identify predictors of
recovery(27), and 3) evaluate predictors of disability and work status in early CRPS.(28) Partner
sites were asked to identify eligible subjects as they presented for clinic visits. Adult subjects
(≥18 years) diagnosed using the IASP 1994 criteria(29,30) with acute (<12 weeks) CRPS type 1
of any limb, with no previous history of CRPS were eligible for the study. However only those
who met the IASP Budapest research criteria for CRPS were included in the current analysis.
Additional inclusion criteria were English literacy, and ability to provide informed consent.
After providing informed consent, participants were assessed on three occasions: 1) at referral
(4-116 days after symptom onset), 2) at 6 months after symptom onset, and 3) at 12 months after
symptom onset. See Figure 1 for a flow diagram of study recruitment. The original study was
approved by the New Zealand Ministry of Health Northern Y ethics committee. Data available
for analysis consisted of participant demographics, clinical characteristics, the CRPS Severity
Score (CSS),(31) and self-reported questionnaires including the SF-MPQ2,(16) and the Pain
Disability Index (PDI).(32,33) The source study also collected data using the short Tampa scale
for Kinesiophobia (34), Pain Catastrophizing Scale (35) Depression Anxiety Stress Scale-21
(36), the Bath Body Perception Disturbance Scale for CRPS (37), and work status. See Figure 2
for a complete listing of the variables utilized for our analysis.
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Figure 1. Flow diagram of overall study participation
Description of outcome measures
Short-Form McGill Pain Questionnaire, Version 2 The SF-MPQ2 contains 22 pain descriptors
(scored 0 – 10 using the anchors ‘none’ to ‘worst possible’) on 4 subscales representing
continuous, intermittent, neuropathic or affective features.(24) The developers reported good
internal consistency for each subscale (ranging from 0.73 – 0.87 across several investigations in
large samples), and discriminant validity was supported by significant differences in change
scores across a clinical trial in those who considered themselves improved compared to those
who did not (p<0.002 for all scales).(24)
CRPS Severity Score The CSS is a 17 item condition-specific clinician rating scale for CRPS
signs which closely aligns with the Budapest diagnostic criteria(31,38). It addresses sensory,
autonomic, vasomotor, motor and trophic features, (rated 1/0 as present/absent), and has
demonstrated discriminative validity to distinguish between CRPS and other forms of chronic
pain (30). More recently, the scale was modified to 16 items to give equal weighting to signs
and symptoms: a multi-site prospective study reported acceptable stability (ICC=0.67) over a 3
month period in persons with chronic (stable) CRPS, and change in CSS scores in persons with
acute CRPS were significantly correlated with changes in pain intensity, and Rand-36 pain,
fatigue, well-being, social functioning, and physical roles subscale scores.(39)
Pain Disability Index The PDI is a brief 7-item self-reported evaluation of the impact of pain on
activities and daily functioning, using 0-5 ratings for each item.(32) It demonstrated good
internal consistency (α=0.86) in a large cross-sectional sample, but lower test-retest reliability
over a 2 month period (r=0.44, p<0.001).(40) Several studies have supported discriminant
validity for distinguishing between persons with high or low levels of disability (32,33,40)
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Figure 2. Variables available for analysis
Data analysis
All data sets from each time point were included in the overall analysis. For analyses requiring
only cross-sectional data, the longitudinal data was transformed (or ‘stacked’) by consideration
of repeated measures from individual participants as unique data points based on duration of
CRPS symptoms. Cases with missing values for any items were excluded from the analysis of
Cronbach’s alpha (reliability); however, the number of cases included in each analysis is clearly
specified in the reporting. For Rasch modelling, only integers are permitted as data for scaling;
therefore a small number of responses indicating a half value were rounded up (i.e. a response of
7.5 would be transformed to 8; this accounted for less than 2% of the study values).
Rasch analysis was conducted using RUMM2030 software (Rumm Laboratory Pty Ltd, Perth,
Australia) and following Tennent et al.’s iterative steps for Rasch modelling:(14,41) see Table 2
for a brief overview of this process. For a detailed description of a worked Rasch analysis
intended for a clinical audience, the reader is referred to Packham & MacDermid.(41) Using
RUMM2030 software constrains the analysis to 9 categorical person-level factors to be used to
describe the sample or test population relative to the construct of interest: refer to Figure 2 for
the variables used here. These person-level factors are also considered to develop the ‘location’,
a Rasch rating of the item severity, which can be understood as how much of the construct of
interest is required for a respondent to endorse any level of an individual item. For analysis of
reliability, validity and responsiveness, data were imported into STATA13 (StataCorp, College
Station, TX) for statistical calculations, including:
Cronbach’s alpha for the total scale and for the NeQ subscale
Validity exploration testing the hypotheses that a) self-reported SF-MPQ2 total and SFMPQ2 NeQ scores will be substantially correlated to pain scores measured by a numeric
rating scale and to PDI scores, and b) SF-MPQ2 NeQ scores will be moderately
correlated to clinician-generated CSS scores. Strength of the correlations were
interpreted employing Landis & Koch’s recommendations where r=0 -.20 is considered
slight, r= .21 – 40 is fair, r= .41-.60 is moderate, r= .61 - .80 is substantial, and r> .80 is
considered excellent.(42)
Responsiveness of the SF-MPQ2 was estimated using the effect size and standardized
response means, and compared to the effect sizes and standardized response means of the
pain Numeric Rating Scale (NRS), PDI and CSS over the same interval.
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Table 2. Overview of the statistical analyses included in Rasch modelling (adapted from
Packham & MacDermid) (34)
RASCH ANALYSIS METHOD OF
HYPOTHESIS/
COMPONENT
ANALYSIS
EVALUATIVE CRITERIA
Log-likelihood ratio
If rating scale parameters are confirmed by a
Partial credit vs.
non-significant ratio test, then items do not
rating scale
vary from the core rating scale structure, and a
parameters
Response distribution

Frequency plot of actual
responses across all possible
items and response options

Thresholds

Graphic representation and
plots of probability

Item fit

Chi-square, fit residual
transformed to a
standardized (Z) score

Person fit

Chi-square, fit residual
transformed to a
Z-score

Item trait interaction

Chi-square probability

Individual person fit

Chi-square analysis

Person separation
index

Cronbach’s alpha

Local dependency

Correlation analysis of item
residuals
Item characteristic curves &
ANOVA of item residuals

Differential item
functioning
Unidimensionality

Principal component factor
analysis is used to identify
positive and negatively
loading items; these
repeatedly t-tested against
each other to ensure they are
not significantly different;
the proportion of significant
t-tests is reported

rating scale format may be utilized. If the test
is significant, a partial credit model is used
Each possible category of item/response
should be used (this visually maps floor or
ceiling effects); ideal to have at least 5 cases
for each rating level of every item to ensure
adequate analysis power
Ordered progression of thresholds (the point
where there is a 50/50 probability of choosing
either response option) from less to more of
the latent trait of interest
Mean 0, SD up to 1 if data fit the Rasch
model; reflects the divergence between
expected and actual values looking across all
items scored by an individual person
Mean, SD up to 1 if data fit the Rasch model;
reflects the divergence between expected and
actual values looking across all persons for a
given item
p>0.05 tests whether the items are working as
expected (fitting the model) across the class
intervals for the trait
Values should fall within ±2.5 if the data fit
the Rasch model
Values over 0.70 allow for group comparison,
over 0.85 for individual comparisons of
summed scores
Correlations of less than 0.3 suggest no firm
evidence of local dependency
IC curves plotted by person characteristics
(such as gender or age) and p>0.05 for
between groups ANOVA reveal no evidence
of DIF
The proportion of significant t-tests will be
less than 0.05 (or less than 5%) and/or if the
95% confidence interval includes 0.05,
unidimensionality is supported

Key: SD = standard deviation; ANOVA = analysis of variance; IC = item characteristic; DIF =
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differential item functioning
RESULTS

Demographics and person characteristics
Fifty-nine participants in the Auckland study met the IASP Budapest research criteria for
CRPS(30) and were included in this analysis. Table 3 describes the demographics and clinical
characteristics of this sample who were initially evaluated an average of nine weeks after the
development of CRPS symptoms.(27)
Table 3. Demographics for sample N=59
Characteristic
Age
Duration of symptoms at baseline
evaluation
Pain at baseline (NRS/10)
CSS at baseline (/17)
Total SF-MPQ2 (/10) at baseline
NeQ subscale score at baseline (n=59)

Mean
48.2 years
67.8 days

SD
13.3
24.3

Range
18 - 72
4 - 116

5.5
12.6
4.1
3.9

2.0
2.0
2.1
2.0

1 - 10
8 - 17
0.27 - 10
0.3 - 10

NeQ subscale score at 6 months (n=57)
NeQ subscale score at 1 year (n=56)

2.3
1.9

2.2
2.2

0 - 9.2
0 – 9.7

Total PDI at baseline

38.1
Frequency
F=43
M=16
R U/E= 33
L U/E=21
R L/E=3
L L/E=1
Multiple= 1
None/minor=5
Soft tissue=2
Minor surgery=21
Fracture=20
Fracture+surgery=11

14.2

Gender
Affected limb

Etiology

14 - 67
Percent
72.9 %
27.1 %
55.9 %
35.6 %
5.1 %
1.7 %
1.7 %
8.5 %
3.4 %
35.6 %
33.9 %
18.6 %

Key: CSS= CRPS Severity Score, NeQ= Neuropathic Qualities, NRS= Numeric Rating Scale, PDI=Pain Disability
Index, SD=standard deviation, SF-MPQ2= Short-Form of the McGill Pain Questionnaire (version 2), F=female,
M=male, R=right L=left, U/E= upper extremity, L/E=lower extremity
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Rasch analysis of the NeQ scale of SF-MPQ2
The total of complete data sets available for this analysis after considering repeated measures
data as cross-sectional were n=156. The log likelihood ratio was calculated at p>0.05, therefore
the partial credit model was utilized for analysis(14): this verifies there is not a common scale
structure across all items, because the intervals between any two points on the scale may vary
both within and across items.(43) The distribution of responses failed to meet the suggested
criteria of at least 5 responses per scoring level per item(14), as participants tended to use lower
scores, reflecting their recovery over the 3 measurement periods (see Table 4). More than half
(n=34) failed to meet Linacre’s conservative suggestion of at least 10 endorsements per scoring
level.(44) Thresholds for all 6 items on the NeQ scale were ‘disordered’ i.e. did not follow the
expected progression for severity of neuropathic pain, and required rescoring by collapsing of
scoring categories. The final scales ranged from 4-6 response options (instead of original 11
response options [0-10]). The solutions for combining categories were also not uniform,
therefore this would be very difficult to operationalize in practice.
Table 4. Distribution of scoring and endorsements (n=157)
Item/Score
Burning
Freezing
Pain with touch
Itching
Tingling
Numbness

0
72
95
52
88
31
40

1
11
7
20
9
18
11

2
9
9
12
19
13
9

3
10
12
9
11
11
19

4
6
9
12
6
13
14

5
11
4
6
2
17
12

6
8
8
13
7
11
5

7
6
3
6
5
9
11

8
13
6
19
4
16
16

9
7
2
4
2
9
8

10
4
2
4
4
9
12

Key: Italicized numbers represent the number of endorsements (or participant selection of) the different scores

Threshold analysis Figure 3a provides a visual illustration of the disordered thresholds for the
‘Tingling’ item. The lines represent the probability of an individual choosing any given scoring
level (0-10) relative to their predicted level of the construct of interest (or person [dis]ability):
neuropathic pain. The figure (Figure 3a) demonstrates a near complete overlap of the probability
curves for a score of 0, 1, and 2. In other words, because these curves are located below the
average item score which is centred at 0 logits on the x axis, the probability of participants with a
low level of neuropathic pain scoring 0, 1, or 2 is unpredictable. Scores using this 0-10 structure
on this item do not follow the anticipated pattern of increasing proportionally as participants
have more neuropathic pain. However, after collapsing the scoring categories (in this case by
combining the scores of 1&2, 3-5, 6&7, 8&9, and retaining a score of 0 or 10 in the original
form, yielding a new six level (0-5) scoring structure, the probability curves demonstrate a
distinct and orderly progression across the person location values (Figure 3b).
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Figure 3A: Probability curve for ‘Tingling’ before correction of thresholds.
Key: The lines represent the probability of an individual choosing any given scoring level (0-10
in 1A; 0-5 in 1B) relative to their predicted level of Tingling.

Figure 3B: Probability curves for ‘Tingling’ after collapsing of categories to correct thresholds
Item and person fit After threshold correction, item fit to the Rasch model was acceptable (mean
set to 0 logits, SD=0.50, with fit residuals of x= -0.28 logits, SD 1.00); no misfitting items were
identified and there was good distribution of items across the difficulty levels, supporting good
targeting of the scale.(6,45) Person fit statistics were also acceptable, (x=-1.17 logits, SD 1.13),
but the negative mean score relative to the average difficulty of the items reflects the generally
low scores on the SF-MPQ2 NeQ subscale (starting at 4.1/10 at baseline and decreasing over
time). This suggests the participants in the sample were better (i.e. had less neuropathic pain)
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than the predicted scale average. Looking at individual person fit, 13 ‘extreme’ cases were
identified: 12 had extremely low scores while one reported 10/10 pain on most items at final
evaluation. A simple clinical interpretation is the predicted vs. observed scores on the NeQ were
not what would be expected given the ratings or ‘person characteristics’ on the other measures:
therefore the person’s reported pain scores did not fit with the rest of their clinical picture.
Taken together, these statistics can be interpreted as reflecting the recovery of participants across
the longitudinal data collection period: this is further supported by the mean scores of the SFMPQ2 NeQ subscale at the 3 different measurement points recorded in Table 4.

Local dependency and differential item function
Local dependency was found between one item pairing, ‘Burning’ and ‘Numbness’. This occurs
when there is a high correlation between two items representing distinct concepts, violating the
assumption items on a scale are independent of each other.(9) Uniform differential item function
was indicated between the ‘Pain with touch’ item and the CSS, suggesting participants scored
the ‘Pain with touch’ item differently at different levels of CRPS severity [F(156,5)=5.07,
p=0.0002]. Table 5 shows the average score on the ‘Pain with touch’ across the CSS scores.
To address both differential item functioning and local dependency, we employed a strategy
common to Rasch analysis and bundled the items to create subtests(14) within the NeQ subscale:
thereby creating Subtest A = Burning, Pain with light touch and Numbness [to address the local
dependency detailed above], and retaining the remaining items Cold/freezing, Tingling, and
Itching independently. This strategy resolved both the differential item function and local
dependency, while maintaining fit to the model (see Table 6). It is important to note that no DIF
was found for duration of CRPS symptoms, which suggests the rating scales operated similarly
across time points. [Insert Tables 5 & 6 about here]

Person separation index and Cronbach’s alpha
After correction for the differential item functioning (DIF) and local dependency, the person
separation index for the proposed model was 0.78, with the inclusion of all cases. This suggests
the scale is able to discriminate between at least 2 groups, but falls below the suggested level of
0.85 for individual level precision.(14) After rescoring of thresholds, internal consistency
(Cronbach’s alpha) based on the rescored items is 0.81 for the 6 items of the NeQ subscale of the
SF-MPQ2, but drops to 0.70 when the scale is partitioned to address DIF and local dependency.

Unidimensionality
After principal components factor analysis to identify negatively and positively loading items, ttesting estimated these items sets as different in only a very small proportion of the comparisons
p= 0.032 [95%CI 0.002 -0.066], which clearly meets the standard of p<0.05 to support
unidimensionality.(46)

Psychometric estimates from classical test theory

13

Internal consistency Cronbach’s alpha for the total SF-MPQ2 scale was estimated at α= 0.96,
and α= 0.83 for the NeQ subscale. The item-total correlation estimate above 0.95 for the entire
scale suggests redundancy exists for this population(47) while the estimate for the NeQ subscale
would be considered good.(48)
Construct validity Regression analyses to explore a priori validity hypotheses confirmed all of
the hypotheses in both strength and direction of the relationships, supporting convergent
construct validity. The results of the regression analyses are summarized in Table 7.
Responsiveness The NeQ subscale of the SF-MPQ2 appeared to adequately assess change over
the interval of baseline to one-year post development of symptoms. Effect sizes and
standardized response means for the NeQ subscale, as well as the pain NRS, PDI and CSS as
measured over the same interval, are presented in Table 8. [insert Table 8 about here]
DISCUSSION

The Rasch analysis presented here supports use of the NeQ scale for persons with CRPS, albeit
with several limitations. This study describes the application of the Rasch model to the NeQ
scale of the SF-MPQ2, from a dataset collected longitudinally on 59 participants across their first
year of CRPS symptoms. The sample demographics were very characteristic of CRPS, with
more women than men, more involvement of the upper extremity than lower, and fractures
reported as the most common precipitating event.(49) The participants were each seen 3 times
for measurement, and the data were transformed , allowing for the cross-sectional analysis of
n=157 complete datasets. Rasch analysis relies on large samples to support the probabilistic
modelling required.(9) Given that 11 of the 66 possible scoring categories were under-utilized in
this sample, we must assume the entire analysis was underpowered because of an uneven
distribution of scores. This variability in score distribution can in part be attributed to the
recovery of the study participants across the study period. Our finding of disordered thresholds
for all six items is also a likely reflection of an underpowered analysis.(44,50) Turner et al. (26)
conducted a Rasch analysis of the SF-MP2 and NeQ scale (n=240 participants with knee OA
completed these questionnaires): they were unable to fit the entire SF-MPQ2 to the Rasch model,
but reported good fit of the NeQ subscale and generated a ‘Rasch conversion’ table for the total
NeQ score.(26)
Because our study was a post-hoc analysis of existing data, the variables available to describe the
person-level factors were based on constructs intended to inform other investigations.(27,28)
Nonetheless, these constructs included a condition-specific measure of symptom severity (the
CSS), a global rating of pain (NRS), and pain-related disability (PDI). Additional variables used
to build the Rasch model were age, gender, and duration of symptoms. This generated a model
of item difficulty that was well targeted across the spectrum of sample characteristics; however,
the average level of neuropathic characteristics experienced by participants was lower than the
average item difficulty on the NeQ subscale. This is concordant with the recovery expected
across the three measurement points given the typical prognosis associated with early diagnosis
of CRPS.(3,51,52)
One of the rationales for conduct of a Rasch analysis is the opportunity to consider the influence
of systematic bias in how items are scored: in Rasch terms, differential item functioning (DIF).
Our analysis identified the potential for DIF in the ‘Pain with light touch’ item, but this influence
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was mediated by simply considering the item alongside other items as a subtest. Allodynia,
which includes pain with touch,(30) is a common feature in CRPS, and has been associated with
poor prognosis in other investigations.(4) It is not discordant to see an almost exponential
increase in the ‘Pain with touch’ score concomitant with an increasing CSS, particularly as
allodynia is incorporated in the CSS as both a sign and symptom. However, it is also important
to note the average score still remained relatively low (the highest mean score was still less than
3/10); again, this likely reflects the clinical recovery seen across the study interval.
Similarly, correlations (local dependency) were seen between the ‘Burning’ and ‘Numbness’
items: this was again addressed by combining the items in a subtest. In short, both the
differential item function and local dependency suggest we could use the 6 Neuropathic Qualities
items of the SF-MPQ2 as a unique scale for the construct of neuropathic pain, but should not use
items individually, and may not be able to reduce the number of items on this subscale without
alteration of the measurement properties of the remaining items (as well as the whole scale).
This is because the estimates of the measurement properties for these individual items were
influenced by their local dependency in this evaluation, and therefore should not be assumed to
be invariant unless both items are used together.(9) This is in contrast to the previous Rasch
analysis which identified a relationship between the ‘Cold/Freezing’ and ‘Numbness’ items.(26)
Furthermore, the person separation index findings suggest a Rasch-corrected NeQ scale based on
our study results may be useful for discriminating between 2 groups in a clinical trial, but may
not be reliable enough to guide individual treatment decisions.(15) The interval level scores
generated by Rasch transformation of the raw data (through the collapsing of scoring categories)
also required re-calculation of all six items: while this is easily achieved by a computer or webbased application, it would demand considerable efforts from clinicians or researchers for data
gathered using the traditional pen-and-paper methods.
From a classical test theory perspective, we were able to generate support for the internal
consistency, construct validity and responsiveness of the NeQ subscale of the SF-MPQ2. The
internal consistency findings were concordant with the Rasch item reliability (α= 0.83 compared
to α= 0.81, respectively). While all of the self-reported measures included in this analysis
demonstrated responsiveness to the substantial changes experienced by most people in this
sample, it is interesting to note the largest effect size was seen for the CSS (see Table 8). This
finding adds to the previously reported psychometric properties of the CSS,(31,39) positioning it
as an outcome measure and not just a screening tool.

Limitations
The number of data sets included in this study (n=156) is above the recommended n=150 for
item calibration(50) but falls below a ‘rule of thumb’ estimate of at least 250 data sets.(53) The
lack of endorsements for all possible responses in our results (Table 4) would suggest
underpowering.(14) There may also be bias introduced by our use of multiple data sets from the
same participants (albeit from different time points). While there are advanced analysis
strategies to check the influence of time-point dependencies in the data, we elected not to apply
these to an underpowered analysis. However, the lack of DIF attributable to CRPS duration (our
time-dependent person factor) suggested the potential time dependencies were not a strong
influence on item measurement properties. Other limitation include that our data were gathered
from a single health district in a single country, and the results may not be fully generalizable.
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Using a heterogeneous sample of participants with various forms of neuropathic pain in future
would also support examination of potential differential item functioning on the basis of
diagnosis: something we were unable to accomplish in our sample where all participants
included in the analysis met the IASP Budapest criteria for the diagnosis of CRPS. Finally, as
this was a secondary analysis of existing data, we were unable to strategically select
theoretically-informed person factors for defining item severity and functioning in this
population; instead, we were limited to selecting from existing variables.
One final point of consideration is that while we examined construct validity of the NeQ
subscale, we did not directly address content validity in this study. We did not directly ask the
question if the NeQ accurately represents the pain qualities experienced by persons with CRPS.
The substantial correlation (r=0.63) seen between NeQ and CSS scores could be considered
preliminary evidence for this form of validity; however we would advocate for the need for
continued investigations to build evidence for content validity, including face validity, relevance
and comprehensiveness.(54) Further, our sample may not have been the ideal study population,
as the improving scores and low score averages reflected a recovery trajectory that may not be
seen in other settings.
In conclusion, on the basis of this Rasch analysis, pain clinicians can consider using the NeQ
subscale of the SF-MPQ2 as a ‘stand-alone’ outcome measure for the neuropathic features of
CRPS if substantial data transformations are made in the background. Replicating this analysis
using a larger sample would increase the confidence in these results. From a classical test theory
perspective, this examination generated preliminary support for the validity and responsiveness
of the NeQ subscale in the CRPS population. However, test-retest reliability for this population
group is still unknown: a key consideration given the variability associated with CRPS.(22)
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